Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial

Am J Kidney Dis. 2019 Nov;74(5):713-715. doi: 10.1053/j.ajkd.2019.03.432. Epub 2019 Jun 27.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzhydryl Compounds / administration & dosage*
  • Blood Glucose / metabolism*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetic Nephropathies / epidemiology
  • Diabetic Nephropathies / etiology
  • Diabetic Nephropathies / prevention & control*
  • Dose-Response Relationship, Drug
  • Global Health
  • Glucosides / administration & dosage*
  • Humans
  • Prevalence
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Sodium-Glucose Transporter 2 Inhibitors / administration & dosage
  • Treatment Outcome

Substances

  • Benzhydryl Compounds
  • Blood Glucose
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin